Shares of CryoLife, Inc. (NYSE:CRY) have earned a consensus recommendation of “Hold” from the seven brokerages that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $23.63.

A number of research analysts have recently commented on the company. Canaccord Genuity reiterated a “buy” rating and issued a $25.00 price target on shares of CryoLife in a research note on Monday, October 9th. Lake Street Capital increased their price target on CryoLife to $26.00 and gave the company a “buy” rating in a research note on Wednesday, October 11th. Zacks Investment Research cut CryoLife from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. BidaskClub cut CryoLife from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Finally, TheStreet cut CryoLife from a “b” rating to a “c+” rating in a research note on Monday, October 30th.

CryoLife (NYSE:CRY) opened at $19.05 on Friday. CryoLife has a 12 month low of $14.02 and a 12 month high of $24.00. The company has a market capitalization of $637.37, a price-to-earnings ratio of 46.46 and a beta of 0.82. The company has a quick ratio of 4.88, a current ratio of 5.96 and a debt-to-equity ratio of 0.29.

CryoLife (NYSE:CRY) last announced its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.08 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.08. CryoLife had a return on equity of 6.43% and a net margin of 5.28%. The company had revenue of $44.00 million during the quarter, compared to analysts’ expectations of $44.60 million. During the same period in the prior year, the company earned $0.13 EPS. CryoLife’s revenue was down 2.9% compared to the same quarter last year. sell-side analysts predict that CryoLife will post 0.42 earnings per share for the current fiscal year.

In related news, CEO James P. Mackin sold 43,050 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $22.09, for a total transaction of $950,974.50. Following the completion of the transaction, the chief executive officer now directly owns 398,399 shares of the company’s stock, valued at approximately $8,800,633.91. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO James P. Mackin sold 125,000 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $22.01, for a total value of $2,751,250.00. Following the transaction, the chief executive officer now directly owns 398,399 shares of the company’s stock, valued at $8,768,761.99. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 171,050 shares of company stock valued at $3,769,825. 6.00% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in CRY. Wells Fargo & Company MN raised its position in CryoLife by 16.5% during the 1st quarter. Wells Fargo & Company MN now owns 31,042 shares of the medical equipment provider’s stock worth $517,000 after purchasing an additional 4,399 shares during the last quarter. Karp Capital Management Corp bought a new position in shares of CryoLife in the 1st quarter worth about $172,000. Ameriprise Financial Inc. raised its position in shares of CryoLife by 4.6% in the 1st quarter. Ameriprise Financial Inc. now owns 162,996 shares of the medical equipment provider’s stock worth $2,714,000 after acquiring an additional 7,228 shares in the last quarter. Parametric Portfolio Associates LLC raised its position in shares of CryoLife by 153.7% in the 1st quarter. Parametric Portfolio Associates LLC now owns 74,646 shares of the medical equipment provider’s stock worth $1,243,000 after acquiring an additional 45,218 shares in the last quarter. Finally, Prudential Financial Inc. raised its position in shares of CryoLife by 1.0% in the 1st quarter. Prudential Financial Inc. now owns 46,503 shares of the medical equipment provider’s stock worth $774,000 after acquiring an additional 450 shares in the last quarter. 69.01% of the stock is owned by institutional investors and hedge funds.

WARNING: This report was originally reported by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.watchlistnews.com/cryolife-inc-cry-receives-average-recommendation-of-hold-from-brokerages/1680067.html.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.